Semaglutide antibody formation — January 2024

Anti-drug antibodies (ADAs) to semaglutide are real but uncommon. In the STEP trials, approximately 2.9% of participants developed ADAs, but only about 0.3-0.5% developed neutralizing antibodies (i.e., antibodies that actually block the drug's activity).[1]

If you have confirmed neutralizing ADAs, there are a few options:

1. Switch to tirzepatide (Mounjaro/Zepbound): Different peptide structure, different epitopes. Your anti-semaglutide antibodies won't cross-react. This is the most common approach.
2. Dose increase: Sometimes you can "overpower" non-neutralizing antibodies with higher doses, but if they're truly neutralizing, this usually doesn't work and just wastes medication.
3. Drug holiday: Some immunologists suggest a 3-6 month washout may allow antibody titers to decline, after which re-challenge might work. Evidence for this with GLP-1 agonists specifically is very thin.
4. Switch GLP-1 agonist within class: Liraglutide (Saxenda) has different enough structure that cross-reactivity is unlikely. But it's a daily injection and less effective for weight loss.

I'd push for the tirzepatide switch. It's a GIP/GLP-1 dual agonist so you're getting an additional mechanism of action, AND you're avoiding the epitope your immune system has flagged.

Thank you so much. I hadn't even thought about tirzepatide as an option. My endo mentioned it but I was too upset in the appointment to really process.

Follow up question: is there any way to know in advance if you're more likely to develop antibodies? Like is it genetic?

There's no reliable predictive test currently. ADA formation is influenced by:

• Individual immune system characteristics (HLA type, prior exposures)
• Injection technique (intramuscular injection may be more immunogenic than subcutaneous)
• Product-related factors (aggregation, impurities — theoretically more relevant with compounded formulations vs brand name, though no data confirms this)
• Possibly concurrent immune modulation (some patients on immunosuppressants for other conditions report lower ADA rates, but obviously you wouldn't take immunosuppressants just for this)

The good news is semaglutide was specifically engineered to be less immunogenic than earlier GLP-1 agonists. The 94% sequence homology with native human GLP-1 plus the albumin-binding side chain were designed to reduce immunogenicity. Exenatide (Byetta/Bydureon), which is only 53% homologous to human GLP-1, had much higher ADA rates (~45%).

You drew the short straw, but it's a short straw that comes with good alternatives.

I want to raise a counterpoint: before jumping to the ADA explanation, how confident is the antibody test? Some of these assays have significant false positive rates, especially at low titers. And a positive ADA test doesn't necessarily mean the antibodies are clinically significant.

Other reasons sema can "stop working" at month 8-9:

• Metabolic adaptation — your TDEE has decreased with weight loss, so the same energy intake now results in maintenance or gain
• Behavioral adaptation — many people gradually increase portions as they get used to the reduced appetite
• Psychological tolerance — the "novelty" of reduced appetite wears off and old habits creep back
• Hormonal changes — ghrelin, leptin, and other appetite hormones can partially adapt

I'd want to see the actual titer and whether a confirmatory neutralization assay was done before attributing the plateau entirely to ADAs.